1. Pathogenesis of Gastric Cancer: Genetics and Molecular Classification.
    Ceu Figueiredo et al, 2017 CrossRef
  2. Molecular testing of gastrointestinal tumours
    Matthew Evans et al, 2017, Diagnostic Histopathology CrossRef
  3. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer
    K. Polom et al, 2017, Br J Surg CrossRef
  4. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma
    Smita S Joshi et al, 2017, Future Oncology CrossRef
  5. Molecular classifications of gastric cancers: Novel insights and possible future applications
    Silvio Ken Garattini et al, 2017, WJGO CrossRef
  6. Comparison between Mononucleotide and Dinucleotide Marker Panels in Gastric Cancer with Loss of hMLH1 or hMSH2 Expression
    Jeong Goo Kim et al, 2017, The International Journal of Biological Markers CrossRef
  7. Proposed Molecular and miRNA Classification of Gastric Cancer.
    Valli De re, 0 CrossRef
  8. Personalisierte Therapie von gastrointestinalen Malignomen
    Marianne Sinn et al, 2018, Info Onkol. CrossRef
  9. Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer
    Daniela Cornelia Lazăr et al, 2018, WJG CrossRef
  10. Therapy Implications of DNA Mismatch Repair Deficiency, Microsatellite Instability, and Tumor Mutation Burden
    Maryam Shirazi et al, 2018, Advances in Molecular Pathology CrossRef
  11. Signet ring cell component, not the Lauren subtype, predicts poor survival: an analysis of 198 cases of gastric cancer
    Vladimir Galvão de Aguiar et al, 2019, Future Oncology CrossRef
  12. The promising role of monoclonal antibodies for gastric cancer treatment
    Farzaneh Afshari et al, 2019, Immunotherapy CrossRef
  13. [MSI Metastatic solid tumors treatment and immunotherapies].
    Clémentine Bouchez et al, 2019, Bull Cancer CrossRef
  14. PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer
    Toshiaki Morihiro et al, 2019, Sci Rep CrossRef
  15. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer
    Feng-Hua Wang et al, 2019, Cancer Commun CrossRef
  16. From Molecular Classification to Targeted Therapy for Gastric Cancer in the Precision Medicine Era
    Lara Alessandrini et al, 2019 CrossRef
  17. Diagnostic, Prognostic, Predictive and Therapeutic Tissue Biomarkers in Gastric Cancer
    Vincenzo Canzonieri et al, 2019 CrossRef
  18. Comparison and Applicability of Molecular Classifications for Gastric Cancer
    O. Serra et al, 2019, Cancer Treatment Reviews CrossRef
  19. Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications
    Carolina Martinez-Ciarpaglini et al, 2019, ESMO Open CrossRef
  20. Long-term survival with stable disease after multidisciplinary treatment for synchronous liver metastases from gastric cancer: a case report
    Wenjun Shi et al, 2019, International Journal of Surgery Case Reports CrossRef
  21. Grading der Tumoren des tubulären Verdauungssystems
    H. Bläker, 2016, Pathologe CrossRef
  22. Gastric carcinoma in canines and humans, a review.
    S Hugen et al, 0 CrossRef
  23. Poorly Differentiated Medullary Phenotype Predicts Poor Survival in Early Lymph Node-Negative Gastro-Esophageal Adenocarcinomas
    Christoph Treese et al, 2016, PLoS ONE CrossRef
  24. Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials
    Michael Davidson et al, 2019, European Journal of Cancer CrossRef
  25. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1
    Marina Alessandra Pereira et al, 2019, Mol Diagn Ther CrossRef
  26. Correlations between microsatellite instability and the biological behaviour of tumours
    Guang Yang et al, 2019, J Cancer Res Clin Oncol CrossRef
  27. Histo- and immunohistochemistry-based estimation of the TCGA and ACRG molecular subtypes for gastric carcinoma and their prognostic significance: A single-institution study
    Ju-Yoon Yoon et al, 2019, PLoS ONE CrossRef
  28. Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients
    S. Cedrés et al, 2020, Clin Transl Oncol CrossRef
  29. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade
    Valerie Lee et al, 2016, The Oncologist CrossRef
  30. Progress and challenges in gastroesophageal cancer
    Olbia Serra et al, 2020, Current Problems in Cancer CrossRef
  31. Hypermutation and microsatellite instability in gastrointestinal cancers
    Kizuki Yuza et al, 2017, Oncotarget CrossRef
  32. Gastrointestinal tissue‐based molecular biomarkers: a practical categorisation based on the 2019 World Health Organization classification of epithelial digestive tumours
    Javier I Quezada‐Marín et al, 2020, Histopathology CrossRef
  33. The Better Survival of MSI Subtype Is Associated With the Oxidative Stress Related Pathways in Gastric Cancer
    Lei Cai et al, 2020, Front. Oncol. CrossRef
  34. Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford
    Aser Abrha et al, 2020 CrossRef
  35. Immunohistochemical Expression Pattern of MLH1, MSH2, MSH6, and PMS2 in Tumor Specimen of Iranian Gastric Carcinoma Patients
    Sina Salari et al, 2021, J Gastrointest Canc CrossRef
  36. Panel of significant risk factors predicts early stage gastric cancer and indication of poor prognostic association with pathogens and microsatellite stability
    Payel Chakraborty et al, 2021, Genes and Environ CrossRef
  37. Microsatellite Instability Analysis in Gastric Carcinomas of Moroccan Patients
    Jean Paul Nshizirungu et al, 2021, Genetic Testing and Molecular Biomarkers CrossRef
  38. Impact of microsatellite status on negative lymph node count and prognostic relevance after curative gastrectomy
    Zhenghao Cai et al, 2021, J Surg Oncol CrossRef
  39. The Emerging Role of Liquid Biopsy in Gastric Cancer
    Csongor György Lengyel et al, 2021, JCM CrossRef
  40. A novel genomic classification system of gastric cancer via integrating multidimensional genomic characteristics
    Haiyong Wang et al, 2021, Gastric Cancer CrossRef
  41. Comparing immunotherapies to other frequently used treatments of gastric cancer
    Debora Basile et al, 2021, Expert Review of Clinical Pharmacology CrossRef
  42. Reproduction of the Cancer Genome Atlas (TCGA) and Asian Cancer Research Group (ACRG) Gastric Cancer Molecular Classifications and Their Association with Clinicopathological Characteristics and Overall Survival in Moroccan Patients
    Jean Paul Nshizirungu et al, 2021, Disease Markers CrossRef
  43. Combined Therapy of Locally Advanced Oesophageal and Gastro–Oesophageal Junction Adenocarcinomas: State of the Art and Aspects of Predictive Factors
    Milan Vošmik et al, 2021, Cancers CrossRef
  44. The Epithelial and Stromal Immune Microenvironment in Gastric Cancer: A Comprehensive Analysis Reveals Prognostic Factors with Digital Cytometry
    Wenjun Shen et al, 2021, Cancers CrossRef
  45. Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis
    Run Cong Nie et al, 2021, Ann Surg Oncol CrossRef
  46. Biomarkers in Gastrointestinal System Carcinomas
    Burcin Pehlivanoglu et al, 2022 CrossRef
  47. Gastric Carcinoma with Lymphoid Stroma: A Combination of Mismatch Repair Deficient Medullary Type and Epstein–Barr Virus-associated Gastric Carcinomas
    Meral Uner et al, 2022, Int J Surg Pathol CrossRef
  48. Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
    Ronan J. Kelly et al, 2020 CrossRef
  49. Clinical Implications of Necroptosis Genes Expression for Cancer Immunity and Prognosis: A Pan-Cancer Analysis
    Xin-yu Li et al, 2022, Front. Immunol. CrossRef
  50. MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma.
    M J M van Velzen et al, 2020, Cancer Treat Rev CrossRef
  51. Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies
    Victor Hugo Fonseca de Jesus et al, 2018, Clinics CrossRef
  52. Cancer Study: Cell to the Animal Models
    Cornelia Amalinei et al, 2022 CrossRef
  53. The Roles of Immune Cells in Gastric Cancer: Anti-Cancer or Pro-Cancer?
    Asif Sukri et al, 2022, Cancers CrossRef
  54. Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies
    Yan Li et al, 2022, Nat Commun CrossRef
  55. Combining single-cell sequencing data to construct a prognostic signature to predict survival, immune microenvironment, and immunotherapy response in gastric cancer patients
    Bo Hu et al, 2022, Front. Immunol. CrossRef
  56. Molecular Pathology of Gastric Cancer
    Moonsik Kim et al, 2022, J Gastric Cancer CrossRef
  57. Histone Deacetylase Functions in Gastric Cancer: Therapeutic Target?
    Amandine Badie et al, 2022, Cancers CrossRef
  58. Microsatellite instability in gastric cancer is a predictor of a favorable prognosis
    N.V. Danilova et al, 2022, Arkh. patol. CrossRef
  59. Identification and validation of a PD-L1-related signature from mass spectrometry in gastric cancer
    Xiancong Chen et al, 2023, J Cancer Res Clin Oncol CrossRef
  60. Cancer Study: Cell to the Animal Models
    Cornelia Amalinei et al, 2023 CrossRef
  61. Extracellular volume fraction determined by equilibrium contrast-enhanced computed tomography: correlation with histopathological findings in gastric cancer
    Yusuke Nishimuta et al, 2023, Jpn J Radiol CrossRef
  62. New Advances in Molecular Typing of Gastric Cancer
    志民 江, 2023, ACM CrossRef
  63. Gastric adenocarcinoma with high‑level microsatellite instability: A case report
    Alejandro Alfaro et al, 2023, Mol Clin Oncol CrossRef
  64. Landscape of KRAS, BRAF, and PIK3CA Mutations and Clinical Features of EBV-Associated and Microsatellite Unstable Gastric Cancer
    A. M. Danishevich et al, 2023, Mol Biol CrossRef
  65. Molecular markers as predictors of response to perioperative chemotherapy in locally advanced gastric cancer
    K. A. Oganyan et al, 2023, Usp. mol. onkol CrossRef
  66. Redox Signaling Modulates Activity of Immune Checkpoint Inhibitors in Cancer Patients
    Alessandro Allegra et al, 2023, Biomedicines CrossRef
  67. Multi‐omic analysis in normal colon organoids highlights MSH4 as a novel marker of defective mismatch repair in Lynch syndrome and microsatellite instability
    Matthew Devall et al, 2023, Cancer Medicine CrossRef
  68. Management of Microsatellite Instability High (MSI-H) Gastroesophageal Adenocarcinoma
    Katherine I. Zhou et al, 2023, J Gastrointest Canc CrossRef
  69. Mutational separation and clinical outcomes of TP53 and CDH1 in gastric cancer
    He-Li Liu et al, 2023, World J Gastrointest Surg CrossRef
  70. Management of high risk T1 gastric adenocarcinoma following endoscopic resection
    Jéssica Chaves et al, 2024, Best Practice & Research Clinical Gastroenterology CrossRef
  71. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study
    Ning Li et al, 2024 CrossRef
  72. Landscape of KRAS, BRAF, PIK3CA Genes Mutations and Clinical Features of EBV-Associated and MSI Gastric Cancer
    A. M. Danishevich et al, 2023, Molekulârnaâ biologiâ CrossRef
  73. Application of immune checkpoint inhibitors and microsatellite instability in gastric cancer
    Shi-Yan Yan et al, 2024, World J Gastroenterol CrossRef
  74. The ratio of intratumoral CD15<sup>+</sup> neutrophils to CD8<sup>+</sup> lymphocytes predicts recurrence in patients with gastric cancer after curative resection.
    Junichiro Watanabe et al, 2024, Cancer Rep (Hoboken) CrossRef
  75. Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents
    Yuki Nonomura et al, 2022, Healthcare CrossRef
  76. Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells
    Gabriele Picco et al, 2024 CrossRef
  77. Occult gastric carcinoma with microsatellite instability diagnosed 10 years after excision of metastatic lymph node: a case report
    Yutaka Tamamori et al, 2024, surg case rep CrossRef
  78. Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair
    Akira Ooki et al, 2024, Gastric Cancer CrossRef
  79. An elevated rate of whole-genome duplications in cancers from Black patients
    Leanne M. Brown et al, 2024, Nat Commun CrossRef
  80. Prognostic significance of CD8 and TCF1 double positive T cell subset in microsatellite unstable gastric cancer
    Juhyeong Park et al, 2024, Sci Rep CrossRef